"Characterization of Monoclonal Antibodies Against Stromelysin-3 and Their Use to Evaluate Stromelysin-3 Levels in Breast Carcinoma by Semi-Quantitative Immunohistochemistry."

According to the authors' abstract of an article published in International Journal of Cancer, "Stromelysin-3 (ST3) is a matrix metalloproteinase which is expressed in fibroblastic cells of most human invasive carcinomas and represents a potential new prognostic indicator. Expression of recombinant ST3 forms in Escherichia coli from cDNA constructs indicated that high levels of expression were achieved when the ST3 pro-domain was deleted. The putative mature form of ST3 thus produced and recovered from bacterial inclusion bodies was used to prepare monoclonal antibodies (MAbs) against ST3 by immunization of BALB/C mice. Ten hybridomas producing MAbs against ST3 were obtained and...

Want to see the full article?

• Purchase this article for only $3.00